Table 1.
Pooled DISCOVER-1 and DISCOVER-2 baseline demographics, disease characteristics and concomitant PsA treatment
| GUS Q4W | GUS Q8W | PBO | All patients | |
| Randomised and treated patients (N) | 373 | 375 | 372 | 1120 |
| Male (%) | 56 | 52 | 48 | 52 |
| Age (years) | 46 | 46 | 47 | 47 |
| BMI (kg/m2) | 29 | 29 | 29 | 29 |
| PsA duration (years) | 6 | 6 | 6 | 6 |
| SJC (0–66) | 11.4 | 11.4 | 11.5 | 11.4 |
| TJC (0–68) | 20.8 | 19.9 | 21.0 | 20.6 |
| CRP (mg/dL) | ||||
| Mean | 1.6 | 1.9 | 1.9 | 1.8 |
| Median | 0.9 | 1.0 | 0.9 | 0.9 |
| csDMARD use at baseline (%) | 68 | 68 | 68 | 68 |
| MTX use at baseline (%) | 58 | 56 | 61 | 58 |
| % BSA with psoriasis (0%–100%) | 17 | 16* | 15† | 16‡ |
| PASI score (0–72) | 10 | 9 | 9† | 10¶ |
| FACIT-F (0–52)§ | 31 | 29 | 30† | 30¶ |
Data are mean values unless stated otherwise.
*N=372.
†N=371.
‡N=1116.
§Higher scores indicate less fatigue.
¶N=1119.
BMI, body mass index; BSA, body surface area; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; GUS, guselkumab; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PBO, placebo; PsA, psoriatic arthritis; Q4W/Q8W, every 4 weeks/every 8 weeks; SJC, swollen joint count; TJC, tender joint count.